A U.S. health system analysis covering 2017 to 2025 found rapid growth in cardiac transthyretin amyloidosis diagnoses alongside increased use of technetium-99m scintigraphy and cardiac MRI, while biopsy usage steadily declined. The data signal an imaging-driven diagnostic pathway for ATTR-cardiac amyloidosis. For cardiology and oncology-adjacent stakeholders, the practical consequence is faster diagnostic workflows and fewer invasive procedures, potentially accelerating time-to-treatment. The retrospective design limits causal inference, but the trend across a nine-year window aligns with broader clinical movement toward non-invasive criteria-based diagnosis.